Crude and adjusted* ORs of vaccine-type and overall pneumococcal carriage among children under 5, by percentage increase in 13-valent pneumococcal conjugate vaccine (PCV13) coverage and individual vaccination status, Lao PDR, December 2013–June 2018†; results are shown for complete participant analyses (n=845)
| Crude | Adjusted* | |||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Vaccine-type (VT) carriage | ||||
| PCV13 coverage | 0.983 (0.972 to 0.994) | 0.003 | 0.989 (0.978 to 1.000) | 0.056 |
| PCV13 status | 0.520 (0.356 to 0.759) | 0.001 | 0.619 (0.400 to 0.959) | 0.032 |
| PCV13 effectiveness (%)‡ | 48.0 (34.1 to 64.1) | 0.001 | 38.1 (4.1 to 60.0) | 0.032 |
| Overall pneumococcal carriage | ||||
| PCV13 coverage | 0.996 (0.990 to 1.003) | 0.255 | 0.998 (0.991 to 1.004) | 0.475 |
| PCV13 status | 1.026 (0.778 to 1.356) | 0.859 | 1.094 (0.777 to 1.542) | 0.606 |
| PCV13 effectiveness (%)‡ | −2.6% (−35.6 to 22.2) | 0.859 | −9.4 (-54.2 to 22.3) | 0.606 |
*Adjusted by family income, age, season, number of children under 5 in the household and kindergarten attendance.
†Includes all participants recruited up to June 2017 and the additional 77 participants enrolled up to June 2018 that resided in villages where vaccination data had already been collected.
‡PCV13 effectiveness against VT carriage was one minus the adjusted OR for the association between VT carriage and individual PCV13 status and multiplied by 100.
PCV, pneumococcal conjugate vaccine.